Somatropin

also known as growth hormone · recombinant human growth hormone · Genotropin · rhGH · Norditropin · human growth hormone · Nutropin AQ · Saizen · +37 more

Protein / enzyme biologic targets GHR

Developed for: pituitary deficiency · fetal growth restriction · isolated short stature · Turner syndrome · HIV infectious disease · female infertility · obesity disorder · traumatic brain injury
+66 more
· cystic fibrosis · hereditary endocrine growth disease · infertility disorder · pituitary dwarfism · Prader-Willi syndrome · short bowel syndrome · chronic kidney disease · end stage renal failure · metabolic syndrome X · AIDS dysmorphic syndrome · Crohn disease · endocrine system disorder · hypopituitarism · juvenile idiopathic arthritis · lipodystrophy · Noonan syndrome · Phelan-McDermid syndrome · brain injury · cardiovascular disorder · chronic renal failure syndrome · COVID-19 · heart failure · muscular atrophy · NAFLD1 · osteoarthritis, knee · osteoporosis · ovarian dysfunction · type 1 diabetes mellitus · achondroplasia · amyotrophic lateral sclerosis · arthropathy · autism spectrum disorder · autoimmune disease, multisystem, infantile-onset · cerebral palsy · cirrhosis of liver · constitutional delay of growth and puberty · cystinosis · disease of bone structure · disease related to hematopoietic stem cell transplant · facioscapulohumeral muscular dystrophy · glucose intolerance · HIV wasting syndrome · Hurler syndrome · hypophosphatemic rickets · hypothyroidism · isolated congenital growth hormone deficiency · myopathy · non-acquired pituitary hormone deficiency · osteogenesis imperfecta · panhypopituitarism · persian gulf syndrome · pituitary gland disorder · polycystic ovary syndrome · renal osteodystrophy · SHOX-related short stature · traumatic encephalopathy · Werner syndrome · anorexia nervosa · chromosome 18q deletion syndrome · disease of the tendon · fibromyalgia · growth delay due to insulin-like growth factor type 1 deficiency · ischemic disease · spinal cord injury · systolic heart failure · uterine disorder
Investigated by: Novo Nordisk A/S · Pfizer · EMD Serono · Eli Lilly and Company · Genentech, Inc. · University of Aarhus
+172 more
· Changchun GeneScience Pharmaceutical Co., Ltd. · Merck KGaA, Darmstadt, Germany · Aarhus University Hospital · Massachusetts General Hospital · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Center for Research Resources (NCRR) · The University of Texas Medical Branch, Galveston · Beijing Children's Hospital · Children's Hospital of Fudan University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Shanghai Children's Hospital · The Children's Hospital of Zhejiang University School of Medicine · Tongji Hospital · University of Texas Southwestern Medical Center · Baylor College of Medicine · Federico II University · Huazhong University of Science and Technology · LG Life Sciences · National Institute of Allergy and Infectious Diseases (NIAID) · Nationwide Children's Hospital · Peking University First Hospital · University of Pennsylvania · Weill Medical College of Cornell University · Ascendis Pharma A/S · Beni-Suef University · BioPartners GmbH · Bispebjerg Hospital · Children's Hospital Medical Center, Cincinnati · Children's Hospital of The Capital Institute of Pediatrics · Ferring Pharmaceuticals · Ipsen · LG Chem · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of General Medical Sciences (NIGMS) · National Institute on Aging (NIA) · Oregon Health and Science University · Parc de Salut Mar · Peking Union Medical College Hospital · Post Graduate Institute of Medical Education and Research, Chandigarh · ShangHai Ji Ai Genetics & IVF Institute · Shengjing Hospital · The First Affiliated Hospital with Nanjing Medical University · The Second Hospital of Hebei Medical University · United States Department of Defense · Vanderbilt University · Woman's Health University Hospital, Egypt · Affiliated Hospital of Jiangnan University · Agenzia Italiana del Farmaco · Ain Shams Maternity Hospital · Alexandria University · Altus Pharmaceuticals · Anhui Provincial Hospital · Assistance Publique Hopitaux De Marseille · Baylor Health Care System · Belgian Study Group for Pediatric Endocrinology · Cairo University · Capital Medical University · Carlos III Health Institute · Center for Human Reproduction · Center for Neurological Studies · Centro de Infertilidad y Reproducción Humana · Charite University, Berlin, Germany · Chengdu Women's and Children's Central Hospital · Children's Hospital Los Angeles · Children's Hospital of Chongqing Medical University · Children's Hospital of Nanjing Medical University · Children's Mercy Hospital Kansas City · Children's National Research Institute · Chinese University of Hong Kong · Chongqing Three Gorges Central Hospital · ClinAmygate · Clinique Ovo · Competence Centre on Health Technologies · Corporacion Parc Tauli · all 178 on the full record

Regulatory milestones approvals, filings & regulatory actions · 29 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	ZOMACTON	—	2018-01-30 – 2018-07-19	fda.gov ↗
Label expansions (3)	US (FDA)	OMNITROPE	—	2010-04-23 – 2011-07-22	fda.gov ↗
Label expansions (8)	US (FDA)	HUMATROPE	—	1989-05-10 – 2009-03-12	fda.gov ↗
Label expansions (3)	US (FDA)	NORDITROPIN FLEXPRO	—	2007-05-31 – 2008-10-31	fda.gov ↗
Label expansions (5)	US (FDA)	GENOTROPIN PRESERVATIVE FREE	—	1997-10-31 – 2008-06-12	fda.gov ↗
Label expansion	US (FDA)	NUTROPIN	—	2006-02-23	fda.gov ↗
Label expansions (4)	US (FDA)	NUTROPIN AQ PEN	—	1997-12-17 – 2005-06-28	fda.gov ↗
Label expansion	US (FDA)	SAIZEN	—	2004-11-01	fda.gov ↗
Approved	EU (EMA)	NutropinAq	—	2001-02-15	europa.eu ↗
Approved	US (FDA)	HUMATROPE	—	1986-10-16	fda.gov ↗

Trials 233 · started per year

today

US approved 1986

EU approved 2001

1986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT05660356	Feb 2023 → Feb 2024	pituitary deficiency, traumatic encephalopathy	University of Calgary	Unknown	No outcome recorded
Phase 0	NCT02726542	May 2017 → Apr 2020	NAFLD1	Massachusetts General Hospital	Completed	No outcome recorded
Phase 0	NCT03237117	Jan 2010 → Dec 2017	female infertility	Competence Centre on Health Technologies	Unknown	No outcome recorded
Phase 120 trials · 1 missed
Phase 1	NCT07542886	Apr → Jun 2026 overdue	—	Pfizer	Recruiting	No outcome recorded
Phase 1	NCT06743997	Jan → Apr 2025	—	LG Chem	Completed	No outcome recorded
Phase 1	NCT04042428	Oct 2019 → Jan 2020	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT04085224	Sep 2019 → Jan 2020	—	LG Chem	Completed	No outcome recorded
Phase 1	NCT03123913	Dec 2017 → Mar 2022	facioscapulohumeral muscular dystrophy	University of Rochester	Completed	No outcome recorded
Phase 1	NCT02359695	Oct 2013 → Dec 2016	infertility disorder	Centro de Infertilidad y Reproducción Humana	Completed	No outcome recorded
Phase 1	NCT01265017	Jul 2012 → Jun 2020	type 1 diabetes mellitus	Sansum Diabetes Research Institute	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT01440686	Sep → Dec 2011	pituitary deficiency	HanAll BioPharma Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01613573	Mar → Oct 2010	pituitary deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01699308	Dec 2009 → Apr 2014	traumatic brain injury	Joe Springer	Completed	No outcome recorded
Phase 1	NCT01010425	Nov 2009 → Feb 2010	—	Ascendis Pharma A/S	Completed	No outcome recorded
Phase 1	NCT01130376	Sep 2009 → Oct 2011	HIV infectious disease	Imperial College London	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00803179	Nov 2008 → Mar 2012	cystic fibrosis	University of Massachusetts, Worcester	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00737113	Sep 2008 → May 2012	disease related to hematopoietic stem cell transplant	Mitchell Horwitz, MD	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT00455260	Apr → Oct 2007	pituitary deficiency	Teva Neuroscience, Inc.	Completed	No outcome recorded
Phase 1	NCT00663611	Oct 2006 → Oct 2014	—	National Institute on Aging (NIA)	Completed	No outcome recorded
Phase 1	NCT01502137	Jun → Nov 2005	end stage renal failure	Novo Nordisk A/S	Completed	Missed primary
Phase 1	NCT00473187	Aug 2004 → Aug 2009	hereditary endocrine growth disease, hypophosphatemic rickets	University of Rostock	Unknown	No outcome recorded
Phase 1	NCT00470002	May 2004 → Jan 2005	cardiovascular disorder	Hannover Medical School	Completed	No outcome recorded
Phase 1	NCT00931476	Apr → Jun 2000	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded

Phase 1/26 trials
Phase 1/2	NCT07036003	Oct 2025 → Jul 2028 expected	osteoarthritis, knee	Dr. David Wasserstein	Recruiting	No outcome recorded
Phase 1/2	NCT05105685	Jun 2020 → May 2021	Phelan-McDermid syndrome	Affiliated Hospital of Jiangnan University	Completed	No outcome recorded
Phase 1/2	NCT03288103	Feb 2018 → Mar 2023	isolated short stature	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1/2	NCT02179255	Aug 2014 → Jun 2021	female infertility	Center for Human Reproduction	Unknown	No outcome recorded
Phase 1/2	NCT02124070	Mar 2014 → Nov 2015	cystinosis, myopathy	National Human Genome Research Institute (NHGRI)	Withdrawn	No outcome recorded
Phase 1/2	NCT00130286	Mar 2005 → Aug 2010	HIV infectious disease, lipodystrophy, metabolic syndrome X	Weill Medical College of Cornell University	Completed	No outcome recorded
Phase 235 trials · 2 met primary · 3 missed
Phase 2	NCT06354023	Feb 2025 → Feb 2026	osteoarthritis, knee	John Sledge	Suspended	No outcome recorded
Phase 2	NCT05355272	Mar 2024 → Dec 2026 expected	persian gulf syndrome, pituitary deficiency	Baylor College of Medicine	Recruiting	No outcome recorded
Phase 2	NCT05382637	Aug 2022 → Sep 2023 overdue	hereditary endocrine growth disease	Children's National Research Institute	Active not recruiting	Met primary
Phase 2	NCT05187377	Jan 2022 → Jan 2025	Phelan-McDermid syndrome, autism spectrum disorder	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 2	NCT04375657	Nov 2020 → Dec 2025 overdue	—	Intervene Immune, Inc.	Recruiting	No outcome recorded
Phase 2	NCT04121780	Oct 2019 → Mar 2025 overdue	hypopituitarism, pituitary deficiency, traumatic brain injury	Center for Neurological Studies	Recruiting	No outcome recorded
Phase 2	NCT04003207	Sep 2019 → Jun 2020	Phelan-McDermid syndrome	Swathi Sethuram	Completed	No outcome recorded
Phase 2	NCT03373149	Nov 2017 → Jul 2020	female infertility	Riyadh Fertility and Reproductive Health center	Unknown	No outcome recorded
Phase 2	NCT02217345	Jun 2017 → Aug 2021	NAFLD1	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT03104010	Apr 2017 → Feb 2022	pituitary deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT02616562	Mar 2016 → Sep 2024	pituitary deficiency	Novo Nordisk A/S	Completed	Missed primary
Phase 2	NCT02946606	Jan 2015 → Dec 2016	pituitary deficiency	Genexine, Inc.	Completed	No outcome recorded
Phase 2	NCT02042170	Feb 2014 → Mar 2015	—	LG Life Sciences	Completed	No outcome recorded
Phase 2	NCT01298960	Feb 2011 → Jun 2013	—	Fundacion Dexeus	Terminated	No outcome recorded
Phase 2	NCT01235273	Jan 2011 → Feb 2014	heart failure	Federico II University	Suspended	No outcome recorded Stop: Enrollment
Phase 2	NCT01090778	Oct 2010 → Dec 2011	pituitary deficiency	Aarhus University Hospital	Completed	No outcome recorded
Phase 2	NCT01204840	Sep 2010 → May 2015	infertility disorder, ovarian dysfunction	Ottawa Fertility Centre	Completed	No outcome recorded
Phase 2	NCT01169103	Mar 2010 → Apr 2013	obesity disorder	Massachusetts General Hospital	Completed	Mixed
Phase 2	NCT03221933	Dec 2009 → Dec 2014	fetal growth restriction	Changchun GeneScience Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT00766038	Sep 2008 → Jun 2013	traumatic brain injury	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT00635960	Mar 2007 → Jul 2009	amyotrophic lateral sclerosis	Federico II University	Completed	No outcome recorded
Phase 2	NCT00488124	Nov 2005 → Feb 2011	isolated short stature	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 2	NCT00297713	Jul 2005 → Jun 2006	pituitary deficiency	Altus Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00109473	Apr 2005 → Jul 2009	Crohn disease	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 2	NCT00102258	Jan 2005 → Oct 2007	constitutional delay of growth and puberty, isolated short stature, pituitary dwarfism	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 2	NCT00080483	Mar 2004 → Sep 2010	hypogonadism, hypopituitarism, pituitary deficiency	University of Pennsylvania	Completed	Missed primary
Phase 2	NCT00079742	Sep 2003 → May 2007	cystic fibrosis	Genentech, Inc.	Completed	No outcome recorded
Phase 2	NCT00184652	Apr 2003 → Sep 2005	end stage renal failure	Novo Nordisk A/S	Completed	Mixed
Phase 2	NCT00071240	Oct 2002 → Sep 2007	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00183040	Sep 2002 → Feb 2007	muscular atrophy	National Institute on Aging (NIA)	Completed	No outcome recorded
Phase 2	NCT00254514	Aug 2001 → Oct 2003	disease of bone structure	Novo Nordisk A/S	Completed	Missed primary
Phase 2	NCT00016445	Feb 2001 → Aug 2007	cystic fibrosis	University of Utah	Completed	No outcome recorded
Phase 2	NCT00067860	Oct 1996 → Dec 2006	short bowel syndrome	Emory University	Completed	No outcome recorded
Phase 2	NCT00004340	Jun 1995 → ?	end stage renal failure, renal osteodystrophy	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00001221	Sep 1987 → Sep 2003	Turner syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	Met primary

Phase 2/315 trials
Phase 2/3	NCT07323329	Oct 2025 → Oct 2026 expected	infertility disorder	Beni-Suef University	Recruiting	No outcome recorded
Phase 2/3	NCT06907121	Jun 2025 → Dec 2027 expected	arthropathy	Integrant Pty Ltd	Not yet recruiting	No outcome recorded
Phase 2/3	NCT05900661	Jul → Sep 2023	—	Beni-Suef University	Unknown	No outcome recorded
Phase 2/3	NCT05253287	Feb 2022 → Dec 2024	chronic liver failure, cirrhosis of liver, muscular atrophy	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT03038594	Nov 2015 → Nov 2021	—	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 2/3	NCT01616225	Jun 2012 → Jun 2015	female infertility	Pacific Centre for Reproductive Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 2/3	NCT00511329	Aug 2007 → May 2010	Crohn disease, juvenile idiopathic arthritis	Nationwide Children's Hospital	Terminated	No outcome recorded
Phase 2/3	NCT00286676	Feb 2006	HIV infectious disease	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
Phase 2/3	NCT00675714	Jan 2004 → Sep 2018	—	The University of Texas Medical Branch, Galveston	Terminated	No outcome recorded
Phase 2/3	NCT00600808	Jun 2003 → Jun 2006	pituitary deficiency	BioPartners GmbH	Completed	No outcome recorded
Phase 2/3	NCT00300664	Jul 2002 → Apr 2005	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Royal Marsden NHS Foundation Trust	Completed	No outcome recorded
Phase 2/3	NCT00294918	Sep 2001 → Feb 2003	AIDS dysmorphic syndrome, HIV infectious disease	EMD Serono	Completed	No outcome recorded
Phase 2/3	NCT00294164	Mar 2001 → May 2002	AIDS dysmorphic syndrome, HIV infectious disease	EMD Serono	Completed	No outcome recorded
Phase 2/3	NCT00673309	Jul 2000 → Apr 2011	—	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 2/3	NCT00256555	Feb 2000 → Dec 2018	cystic fibrosis	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded

Phase 368 trials · 13 met primary · 3 missed
Phase 3	NCT07221851	Dec 2025 → Feb 2028 expected	SHOX-related short stature, Turner syndrome, fetal growth restriction, isolated short stature	Ascendis Pharma A/S	Recruiting	No outcome recorded
Phase 3	NCT05447208	Aug 2022 → Mar 2026 overdue	—	ShangHai Ji Ai Genetics & IVF Institute	Recruiting	No outcome recorded
Phase 3	NCT04697381	Feb 2021 → Dec 2022	Prader-Willi syndrome	Pfizer	Completed	Met primary
Phase 3	NCT05574894	Jan 2021 → Jun 2022	—	ShangHai Ji Ai Genetics & IVF Institute	Completed	Met primary
Phase 3	NCT03831880	Feb 2019 → Aug 2020	pituitary deficiency	Pfizer	Completed	Met primary
Phase 3	NCT03554265	Aug 2018 → Oct 2023	COVID-19, cognitive disorder, traumatic brain injury	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 3	NCT03535415	Jun 2018 → Sep 2020	—	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03554031	Apr 2018 → Jan 2020	Prader-Willi syndrome	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03245333	Dec 2014 → Dec 2017	fetal growth restriction	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT01927861	Aug 2013 → Jul 2018	Noonan syndrome	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01778023	Jan 2013 → Dec 2014	isolated short stature	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT01572259	Sep 2011 → Mar 2016	atherosclerotic cardiovascular disease	Assistance Publique Hopitaux De Marseille	Unknown	No outcome recorded
Phase 3	NCT01237340	Oct 2010 → Dec 2011	—	EMD Serono	Terminated	No outcome recorded
Phase 3	NCT00943995	Jul 2010 → Aug 2012	chronic kidney disease	Nationwide Children's Hospital	Completed	No outcome recorded
Phase 3	NCT00884000	Jan 2010 → Jun 2012	pituitary deficiency	Ferring Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00757393	Sep 2008 → Sep 2015	osteoporosis	The Hospital for Sick Children	Completed	No outcome recorded
Phase 3	NCT01529944	Sep → Oct 2008	Noonan syndrome	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00625872	Jul 2008 → Mar 2011	fetal growth restriction	Pfizer	Terminated	Missed primary Stop: Enrollment
Phase 3	NCT00627523	Feb 2008 → Dec 2013	fetal growth restriction	Pfizer	Completed	Met primary
Phase 3	NCT00503698	Jul 2007 → Dec 2008	end stage renal failure	Novo Nordisk A/S	Terminated	Missed primary
Phase 3	NCT01495468	Mar 2007 → Jan 2008	pituitary deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Completed	Met primary
Phase 3	NCT00169637	Jun 2006 → Jun 2008	short bowel syndrome	Hospices Civils de Lyon	Completed	Missed primary
Phase 3	NCT00355030	Jun 2006 → Jul 2015	isolated short stature	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00250250	Oct 2005 → Mar 2006	Turner syndrome	Ferring Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00271518	Sep 2005 → Dec 2013	—	LG Life Sciences	Unknown	No outcome recorded
Phase 3	NCT00444964	Apr 2005 → Jan 2012	Prader-Willi syndrome	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 3	NCT00249821	Feb 2005 → Sep 2007	fetal growth restriction	Merck KGaA, Darmstadt, Germany	Completed	Met primary
Phase 3	NCT00174252	Feb 2005 → Apr 2009	fetal growth restriction	Pfizer	Completed	No outcome recorded
Phase 3	NCT01077960	Feb 2005 → Jan 2006	AIDS dysmorphic syndrome	EMD Serono	Completed	No outcome recorded
Phase 3	NCT00163189	Jan 2005 → Dec 2014	pituitary deficiency	Pfizer	Completed	Met primary
Phase 3	NCT00109733	Jan 2005 → Jun 2006	non-acquired pituitary hormone deficiency, pituitary dwarfism	EMD Serono	Completed	No outcome recorded
Phase 3	NCT00163215	Jan 2005 → Oct 2011	endocrine system disorder	Pfizer	Completed	No outcome recorded
Phase 3	NCT00184730	Nov 2004 → Sep 2006	—	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00184717	Aug 2004 → Mar 2006	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00234533	Jun 2004 → Jul 2008	Turner syndrome, chronic kidney disease, pituitary gland disorder	Ipsen	Completed	No outcome recorded
Phase 3	NCT00082628	May 2004 → Sep 2005	HIV infectious disease, lipodystrophy	EMD Serono	Completed	Met primary
Phase 3	NCT01067352	Feb 2004 → Jul 2009	fetal growth restriction	Merck KGaA, Darmstadt, Germany	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00184743	Dec 2003 → Dec 2005	—	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT02693522	Oct 2003 → Dec 2004	pituitary deficiency	Daewoong Pharmaceutical Co. LTD.	Completed	No outcome recorded
Phase 3	NCT00557336	Jul 2003 → Jun 2005	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00519558	May 2003 → Jan 2005	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00102817	May 2003 → Dec 2006	hereditary endocrine growth disease, pituitary dwarfism	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00191360	Jan 2003 → May 2006	pituitary deficiency	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00191529	Dec 2002 → Jun 2007	fetal growth restriction	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT00184756	Nov 2002 → Jul 2006	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00174291	Mar 2002 → Oct 2011	endocrine system disorder	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00184678	Feb 2002 → Jul 2006	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT01502124	May 2001 → Mar 2003	hereditary endocrine growth disease, pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00174421	Apr 2001 → Aug 2005	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00191074	Feb 2001 → Jan 2006	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT01563926	Oct 2000 → Oct 2002	Turner syndrome, pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00174187	Sep 2000 → Sep 2011	endocrine system disorder	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00262249	Aug 2000 → May 2004	isolated short stature, pituitary deficiency	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT00190658	Feb 2000 → Jul 2004	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00406926	Aug 1999 → Aug 2003	Turner syndrome	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00184691	Apr 1999 → Jun 2005	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00781547	Jan 1999 → Sep 2003	metabolic syndrome X, obesity disorder	Göteborg University	Completed	No outcome recorded
Phase 3	NCT01400698	Nov 1998 → Feb 2010	fetal growth restriction	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 3	NCT00501514	Nov 1997 → Nov 2005	heart failure	Federico II University	Completed	No outcome recorded
Phase 3	NCT00489528	Jul 1997 → Mar 2002	HIV wasting syndrome	EMD Serono	Completed	No outcome recorded
Phase 3	NCT00570011	Jun 1997 → Dec 1998	pituitary deficiency	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00174278	Feb 1997 → Oct 2006	pituitary deficiency	Pfizer	Completed	No outcome recorded
Phase 3	NCT00420251	Mar 1996 → Jul 2006	autoimmune disease, multisystem, infantile-onset, juvenile idiopathic arthritis	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 3	NCT00001305	Nov 1991 → May 2017	osteogenesis imperfecta	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 3	NCT01529840	Jun 1990 → Sep 2005	Noonan syndrome	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT00174408	Mar 1990 → Feb 2005	—	Pfizer	Completed	No outcome recorded
Phase 3	NCT00191113	Feb 1989 → Dec 2007	Turner syndrome	Eli Lilly and Company	Completed	Met primary
Phase 3	NCT01518036	Sep 1987 → Apr 2004	Turner syndrome	Novo Nordisk A/S	Completed	No outcome recorded

Phase 451 trials · 2 met primary · 2 missed
Phase 4	NCT07481656	Apr 2026 → Sep 2027 expected	traumatic brain injury	Anhui Provincial Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07691125	Jul 2024 → Apr 2027 expected	short bowel syndrome	Changchun GeneScience Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 4	NCT05353192	Sep 2022 → Feb 2025	achondroplasia	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT04532554	Oct → Dec 2020	COVID-19	ClinAmygate	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT05281341	Jan 2020 → Dec 2021	female infertility	Alexandria University	Completed	No outcome recorded
Phase 4	NCT03616509	Jun 2017 → Jul 2019	Prader-Willi syndrome	Corporacion Parc Tauli	Completed	No outcome recorded
Phase 4	NCT02311894	Mar 2015 → Nov 2017	pituitary deficiency	Genentech, Inc.	Completed	No outcome recorded
Phase 4	NCT02185326	Jul → Dec 2014	female infertility	Woman's Health University Hospital, Egypt	Completed	Met primary
Phase 4	NCT02195947	Jul 2014 → Jul 2015	female infertility	Cairo University	Completed	No outcome recorded
Phase 4	NCT01715324	Jun 2014 → Jul 2021	infertility disorder	Clinique Ovo	Completed	Missed primary
Phase 4	NCT01897324	Jul 2013 → Jan 2015	female infertility	Woman's Health University Hospital, Egypt	Completed	No outcome recorded
Phase 4	NCT01806298	Jun 2013 → Mar 2016	pituitary deficiency	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 4	NCT01438801	May 2013	isolated short stature	Ipsen	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT01901666	Jan 2013 → Jun 2014	chronic myeloid leukemia, isolated short stature	Post Graduate Institute of Medical Education and Research, Chandigarh	Unknown	No outcome recorded
Phase 4	NCT01853566	Jan 2012 → Jun 2013	—	Federal University of Rio de Janeiro	Completed	No outcome recorded
Phase 4	NCT01246219	Oct 2011 → Nov 2017	isolated short stature	Rabin Medical Center	Completed	No outcome recorded
Phase 4	NCT01052623	Jan 2010 → Dec 2011	ataxia telangiectasia	Johann Wolfgang Goethe University Hospital	Unknown	No outcome recorded
Phase 4	NCT01298180	Jan 2009 → May 2013	Prader-Willi syndrome	University Hospital, Toulouse	Completed	No outcome recorded
Phase 4	NCT00555009	Mar 2008 → Jan 2009	brain injury, pituitary deficiency	Pfizer	Terminated	No outcome recorded
Phase 4	NCT00537914	Feb 2008 → Mar 2022	fetal growth restriction	Sandoz	Completed	No outcome recorded
Phase 4	NCT00840944	Jan 2008 → Jan 2024	isolated short stature	Belgian Study Group for Pediatric Endocrinology	Unknown	No outcome recorded
Phase 4	NCT00432263	Apr 2007 → ?	traumatic brain injury	Pfizer	Withdrawn	No outcome recorded
Phase 4	NCT01187550	Mar 2007 → Sep 2008	pituitary dwarfism	Merck KGaA, Darmstadt, Germany	Completed	Missed primary
Phase 4	NCT01380366	Oct 2006 → Feb 2011	short bowel syndrome	Northwestern University	Completed	No outcome recorded
Phase 4	NCT00307411	Aug 2006 → Jul 2007	metabolic syndrome X	Chinese University of Hong Kong	Unknown	No outcome recorded
Phase 4	NCT00287677	Jan 2006 → Jul 2009	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00266656	Dec 2005 → Sep 2015	Turner syndrome	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT00519844	Jul 2005 → Jan 2006	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT00256126	May 2005 → Sep 2007	Turner syndrome, pituitary deficiency	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 4	NCT00373386	Jan 2005 → Jun 2007	isolated short stature, panhypopituitarism	Ohio State University	Completed	No outcome recorded
Phase 4	NCT00140413	Dec 2004 → Feb 2014	septooptic dysplasia	Children's Hospital Los Angeles	Completed	No outcome recorded
Phase 4	NCT00957671	Nov 2003 → Oct 2015	pituitary deficiency, traumatic brain injury	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 4	NCT00929799	Nov 2003 → Aug 2007	pituitary deficiency	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 4	NCT00742157	Sep 2003 → Oct 2008	short bowel syndrome	University of Nebraska	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01157793	Sep 2003 → Feb 2005	pituitary deficiency	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 4	NCT00206375	May 2003 → Sep 2011	hypothyroidism	Baylor College of Medicine	Terminated	No outcome recorded
Phase 4	NCT00567385	Mar 2003 → Mar 2004	hereditary endocrine growth disease, pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT00352287	Mar 2003 → Apr 2005	abdominal obesity-metabolic syndrome, glucose intolerance, obesity disorder	Stanford University	Completed	No outcome recorded
Phase 4	NCT00638053	Nov 2002 → Nov 2003	brain injury, pituitary dwarfism	Pfizer	Terminated	No outcome recorded
Phase 4	NCT01859949	Oct 2002 → Aug 2015	isolated short stature	Pfizer	Completed	No outcome recorded
Phase 4	NCT01698944	May 2001 → Nov 2002	pituitary deficiency	Novo Nordisk A/S	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01734447	Apr 2000 → Apr 2003	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT00453557	Apr 1999 → Dec 2000	obesity disorder	Pennington Biomedical Research Center	Completed	No outcome recorded
Phase 4	NCT00490191	Jan 1999 → Jul 2001	hypopituitarism	Eli Lilly and Company	Completed	No outcome recorded
Phase 4	NCT01562834	Oct 1998 → Dec 2002	—	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT00184769	Jan 1998 → Dec 2005	chronic renal failure syndrome	Novo Nordisk A/S	Completed	Met primary
Phase 4	NCT00194883	Apr 1997 → May 2003	chronic kidney disease	Weill Medical College of Cornell University	Suspended	No outcome recorded
Phase 4	NCT01734486	Sep 1996 → May 2003	Turner syndrome	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT01697644	Oct 1990 → May 2005	fetal growth restriction	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT01518062	Nov 1989 → Sep 2003	Turner syndrome, autosomal genetic disease	Novo Nordisk A/S	Completed	No outcome recorded
Phase 4	NCT00194961	? → Dec 2007	chronic kidney disease	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Business

Phase not applicable35 trials · 2 met primary · 1 missed
—	NCT07568574	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT07359625	Dec 2025 → Apr 2027 expected	disorder of fatty acid and ketone body metabolism, obesity disorder	University of Aarhus	Recruiting	No outcome recorded
—	NCT05746650	Feb 2023 → Jun 2027 expected	—	Bispebjerg Hospital	Recruiting	No outcome recorded
—	NCT05585177	Nov 2022 → Nov 2024	infertility disorder	Nanjing University	Unknown	No outcome recorded
—	NCT05089344	Oct 2021 → Oct 2022	female infertility	Ain Shams Maternity Hospital	Unknown	No outcome recorded
—	NCT04998500	Aug 2021 → Dec 2023	—	University of Aarhus	Unknown	No outcome recorded
—	NCT04588844	Dec 2020 → Mar 2022	ovarian dysfunction	Shandong University	Unknown	No outcome recorded
—	NCT03966339	Aug 2019 → Dec 2022	female infertility	Reproductive & Genetic Hospital of CITIC-Xiangya	Unknown	Missed primary
—	NCT03878992	Apr 2019 → Mar 2021	pituitary deficiency	University of Aarhus	Unknown	No outcome recorded
—	NCT02655263	Jan 2016 → Oct 2017	—	University of Aarhus	Completed	No outcome recorded
—	NCT02077348	May 2014 → Sep 2015	diabetic ketoacidosis, type 1 diabetes mellitus	University of Aarhus	Completed	No outcome recorded
—	NCT01970800	Jan 2013 → Dec 2014	isolated short stature	Maimonides Medical Center	Withdrawn	No outcome recorded
—	NCT01421589	Sep 2011 → Mar 2013	obesity disorder, pituitary deficiency	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT01299831	Jan 2011 → Dec 2013	—	University of Aarhus	Completed	No outcome recorded
—	NCT00720616	Oct 2010 → Oct 2012	metabolic syndrome X	Oregon Health and Science University	Withdrawn	No outcome recorded
—	NCT00518635	Oct 2010 → Oct 2011	polycystic ovary syndrome	Oregon Health and Science University	Withdrawn	No outcome recorded
—	NCT01209429	Sep 2010 → Sep 2011	—	University of Aarhus	Completed	No outcome recorded
—	NCT01158612	Aug 2010 → Jul 2011	—	University of Aarhus	Completed	No outcome recorded
—	NCT00795210	Feb 2009 → Nov 2012	lipodystrophy	Massachusetts General Hospital	Completed	Met primary
—	NCT00646815	Mar 2008 → Sep 2009	pituitary deficiency	University of Aarhus	Completed	No outcome recorded
—	NCT00568568	Dec 2007 → Feb 2010	—	University of Aarhus	Completed	No outcome recorded
—	NCT00397592	Aug 2006 → Jan 2007	cardiovascular disorder	Vanderbilt University	Completed	No outcome recorded
—	NCT00476879	Aug 2006 → Nov 2007	fatty liver disease	University of Aarhus	Completed	No outcome recorded
—	NCT00286689	Feb 2006	Crohn disease, HIV infectious disease, Hurler syndrome, cerebral palsy +1	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
—	NCT00362063	Jan 2006 → Apr 2018	pituitary deficiency	Baylor College of Medicine	Unknown	No outcome recorded
—	NCT00287430	Jan 2006	cystic fibrosis	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
—	NCT00149708	Sep 2005 → Dec 2009	isolated congenital growth hormone deficiency	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded
—	NCT00512473	Sep 2005 → Apr 2006	—	University of Aarhus	Completed	No outcome recorded
—	NCT00355784	Sep 2005 → Dec 2011	obesity disorder	University of Michigan	Completed	No outcome recorded
—	NCT00131378	Nov 2004 → Nov 2012	obesity disorder	Massachusetts General Hospital	Completed	Met primary
—	NCT00004429	Dec 1999 → Feb 2005	chronic renal failure syndrome	FDA Office of Orphan Products Development	Completed	No outcome recorded
—	NCT00006394	Apr 1997 → ?	osteoporosis, pituitary deficiency	National Center for Research Resources (NCRR)	Completed	No outcome recorded
—	NCT00004815	May 1992 → ?	Werner syndrome	National Center for Research Resources (NCRR)	Completed	No outcome recorded
—	NCT00050921	? → Mar 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00006143	? → Jul 2002	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Comparator or background therapy99 trials
Phase 0	NCT00517062 Comparator	Jan 2006 → Jan 2012	pituitary deficiency	Oregon Health and Science University	Completed	No outcome recorded
Phase 1	NCT06558422 Background	Jan 2027 → Dec 2028 expected	hyperinsulinism, metabolic dysfunction-associated steatotic liver disease, obesity disorder, prediabetes syndrome	Columbia University	Not yet recruiting	No outcome recorded
Phase 1	NCT07016802 Comparator	Jun 2025 → Nov 2026 expected	non-acquired pituitary hormone deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 1	NCT06126354 Background	Jul 2024 → Nov 2025	NAFLD1, prediabetes syndrome	Columbia University	Withdrawn	No outcome recorded
Phase 1	NCT05724134 Background	Aug 2023 → Sep 2025	NAFLD1, hyperinsulinism, obesity disorder, prediabetes syndrome	Columbia University	Completed	No outcome recorded
Phase 1	NCT02114775 Comparator	Dec 2014 → Nov 2017	traumatic brain injury	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded
Phase 1	NCT01973244 Comparator	Dec 2013 → Nov 2014	—	Novo Nordisk A/S	Completed	No outcome recorded
Phase 1	NCT01494779 Comparator	Mar → Jun 2013	pituitary deficiency	Azidus Brasil	Unknown	No outcome recorded
Phase 1	NCT00870220 Background	Apr 2009 → Mar 2011	Turner syndrome	University of Chicago	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT07450053 Comparator	Mar 2026 → Jul 2028 expected	isolated short stature	Changchun GeneScience Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07450001 Comparator	Mar 2026 → Jul 2028 expected	pituitary deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07264595 Comparator	Jan 2026 → Nov 2030 expected	pituitary deficiency	Changchun GeneScience Pharmaceutical Co., Ltd.	Recruiting	No outcome recorded
Phase 1/2	NCT06379659 Comparator	May → Jul 2024	female infertility, uterine disorder	Isfahan University of Medical Sciences	Completed	No outcome recorded
Phase 1/2	NCT04507945 Background	Oct 2020 → Sep 2021	bowel dysfunction	Nanjing University School of Medicine	Unknown	No outcome recorded
Phase 1/2	NCT00684957 Comparator	Jan 2008 → Oct 2012	pituitary deficiency	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT06382155 Comparator	Oct 2024 → Jun 2026 overdue	isolated short stature	BioMarin Pharmaceutical	Recruiting	No outcome recorded
Phase 2	NCT05690386 Comparator	Feb 2023 → Oct 2024 overdue	Turner syndrome	Ascendis Pharma Endocrinology Division A/S	Active not recruiting	No outcome recorded
Phase 2	NCT05838885 Comparator	Feb 2022 → Oct 2023	Turner syndrome, fetal growth restriction, isolated short stature	Xiamen Amoytop Biotech Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT04614337 Comparator	Dec 2020 → Sep 2024	pituitary deficiency	Lumos Pharma	Completed	No outcome recorded
Phase 2	NCT02597660 Comparator	May → Dec 2020	disease of the tendon	Hospital for Special Surgery, New York	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT03878446 Comparator	Jul 2019 → May 2021 overdue	fetal growth restriction	Novo Nordisk A/S	Active not recruiting	No outcome recorded
Phase 2	NCT03717168 Comparator	Mar → Aug 2018	—	National Cancer Institute, Egypt	Completed	No outcome recorded
Phase 2	NCT03309891 Comparator	Jan 2016 → Oct 2017	pituitary deficiency	Genexine, Inc.	Completed	No outcome recorded
Phase 2	NCT02420353 Comparator	May 2015 → Oct 2018	—	University of Michigan	Completed	No outcome recorded
Phase 2	NCT02338206 Comparator	Mar 2015 → Nov 2017	infertility disorder	Woman's Health University Hospital, Egypt	Completed	No outcome recorded
Phase 2	NCT02326610 Comparator	Dec 2014 → Dec 2017	fetal growth restriction	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 2	NCT02092077 Comparator	Apr 2014 → Apr 2016	pituitary deficiency	Teva Pharmaceutical Industries, Ltd.	Terminated	No outcome recorded Stop: Business
Phase 2	NCT01947907 Comparator	Jul 2013 → Jul 2015	—	Ascendis Pharma A/S	Completed	No outcome recorded
Phase 2	NCT01811576 Comparator	Mar → Aug 2013	pituitary deficiency	Teva Branded Pharmaceutical Products R&D, Inc.	Completed	No outcome recorded
Phase 2	NCT01647412 Comparator	Mar 2012 → ?	Crohn disease	Columbia University	Withdrawn	No outcome recorded
Phase 2	NCT01592500 Comparator	Feb 2012 → Jul 2015	non-acquired pituitary hormone deficiency	OPKO Health, Inc.	Completed	No outcome recorded
Phase 2	NCT01397500 Comparator	Nov 2011 → Feb 2015	pituitary deficiency	Max-Planck-Institute of Psychiatry	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01822340 Comparator	Oct 2011 → Jun 2015	pituitary deficiency	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 2	NCT01247675 Comparator	Nov 2010 → May 2011	pituitary deficiency	Ascendis Pharma A/S	Completed	No outcome recorded
Phase 2	NCT00936403 Comparator	Aug 2009 → Jul 2010	—	Novo Nordisk A/S	Completed	No outcome recorded
Phase 2	NCT00837863 Comparator	Mar 2009 → Sep 2010	pituitary deficiency	Altus Pharmaceuticals	Unknown	No outcome recorded
Phase 2	NCT00572156 Comparator	Dec 2007 → Apr 2010	growth delay due to insulin-like growth factor type 1 deficiency	Ipsen	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00283595 Comparator	Jan 2006 → Feb 2009	anorexia nervosa, osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00174460 Comparator	Aug 2005 → Mar 2008	—	Pfizer	Completed	No outcome recorded
Phase 2	NCT00004275 Background	Oct 1999 → Aug 2007	Turner syndrome	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	No outcome recorded
Phase 2	NCT00244075 Comparator	Jul 1998 → Aug 2006	end stage renal failure	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00001343 Background	Dec 1992 → Oct 2007	Turner syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	No outcome recorded
Phase 2/3	NCT04513171 Comparator	Dec 2018 → Jun 2023	pituitary deficiency	Xiamen Amoytop Biotech Co., Ltd.	Completed	No outcome recorded
Phase 2/3	NCT03420144 Comparator	Jan 2018 → Jun 2020	cirrhosis of liver	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT02451033 Comparator	May 2015 → Jun 2016	cirrhosis of liver	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT02879747 Comparator	Dec 2003 → Mar 2012	isolated short stature	Göteborg University	Completed	No outcome recorded
Phase 2/3	NCT00133354 Comparator	Nov 2001 → Aug 2006	hypopituitarism	Nemours Children's Clinic	Completed	No outcome recorded
Phase 3	NCT07226089 Comparator	Feb 2026 → Dec 2027 expected	fetal growth restriction	Rabin Medical Center	Recruiting	No outcome recorded
Phase 3	NCT07309562 Comparator	Jan 2026 → Mar 2028 expected	fetal growth restriction	Xiamen Amoytop Biotech Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT06927310 Comparator	Apr 2025 → Mar 2026 overdue	isolated short stature	Xiamen Amoytop Biotech Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT04867317 Comparator	Jan 2025 → Feb 2027 expected	non-acquired pituitary hormone deficiency, traumatic brain injury	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 3	NCT06103513 Comparator	Dec 2023 → Jun 2025	—	Northwell Health	Unknown	No outcome recorded
Phase 3	NCT06007417 Comparator	Dec 2023 → May 2025	—	Changchun GeneScience Pharmaceutical Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT05330325 Comparator	Aug 2022 → Aug 2024 overdue	Noonan syndrome, Turner syndrome, isolated short stature	Novo Nordisk A/S	Active not recruiting	Met primary
Phase 3	NCT04970654 Comparator	Jul 2021 → Nov 2023	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT04615273 Comparator	Dec 2020 → Nov 2023	pituitary deficiency	Ascendis Pharma Endocrinology Division A/S	Completed	Met primary
Phase 3	NCT03811535 Comparator	May 2019 → Nov 2021	pituitary deficiency	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT03775993 Comparator	Mar 2019 → Mar 2022	heart failure, pituitary deficiency	Federico II University	Unknown	No outcome recorded
Phase 3	NCT03874013 Comparator	Dec 2017 → Mar 2020	pituitary deficiency	OPKO Health, Inc.	Completed	No outcome recorded
Phase 3	NCT03075644 Comparator	Mar 2017 → Oct 2018	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT02781727 Comparator	Dec 2016 → Jan 2019	pituitary deficiency	Ascendis Pharma Endocrinology Division A/S	Completed	Met primary
Phase 3	NCT02968004 Comparator	Dec 2016 → Aug 2019	non-acquired pituitary hormone deficiency	OPKO Health, Inc.	Completed	Met primary
Phase 3	NCT02770157 Comparator	Feb 2016 → Aug 2019	fetal growth restriction	Dong-A ST Co., Ltd.	Completed	Met primary
Phase 3	NCT03033121 Comparator	Jan 2016 → Jan 2017	—	University of Palermo	Completed	No outcome recorded
Phase 3	NCT02339090 Comparator	Aug 2015 → Aug 2017	—	Versartis Inc.	Completed	No outcome recorded
Phase 3	NCT02382939 Comparator	Feb 2015 → Jan 2016	pituitary deficiency	Novo Nordisk A/S	Completed	No outcome recorded
Phase 3	NCT02229851 Comparator	Oct 2014 → Apr 2017	pituitary deficiency	Novo Nordisk A/S	Completed	Met primary
Phase 3	NCT02204163 Comparator	Jun 2014 → Dec 2017	Prader-Willi syndrome	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01813630 Comparator	Feb 2013 → May 2018	Turner syndrome	Dong-A ST Co., Ltd.	Completed	Met primary
Phase 3	NCT01746862 Comparator	Dec 2012 → Aug 2014	isolated short stature	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 3	NCT01329757 Comparator	Apr 2011 → Nov 2015	spinal cord injury	Hospital Nacional de Parapléjicos de Toledo	Completed	No outcome recorded
Phase 3	NCT01248416 Comparator	Nov 2010 → Sep 2016	isolated short stature	Nemours Children's Clinic	Completed	No outcome recorded
Phase 3	NCT01020955 Comparator	Oct 2009 → Nov 2011	type 2 diabetes mellitus	Karolinska University Hospital	Completed	No outcome recorded
Phase 3	NCT00630487 Comparator	May → Oct 2008	pituitary deficiency	Pfizer	Terminated	No outcome recorded
Phase 3	NCT00933686 Comparator	Dec 2007 → Jul 2010	fibromyalgia	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 3	NCT00396097 Comparator	Dec 2006 → Aug 2012	isolated short stature	Pfizer	Completed	No outcome recorded
Phase 3	NCT04420481 Comparator	Apr 2004 → Feb 2012	ischemic disease, systolic heart failure	Göteborg University	Completed	No outcome recorded
Phase 3	NCT00191165 Comparator	Mar 2004 → Apr 2008	pituitary deficiency	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00134420 Comparator	Feb 2001 → Jun 2005	chromosome 18q deletion syndrome, pituitary deficiency	The University of Texas Health Science Center at San Antonio	Completed	No outcome recorded
Phase 3	NCT01073605 Comparator	Jul 1993 → May 2009	fetal growth restriction	Pfizer	Completed	No outcome recorded
Phase 3	NCT00452491 Comparator	May 1993 → Apr 2010	fetal growth restriction	Sanofi	Completed	No outcome recorded
Phase 4	NCT05681299 Comparator	May 2023 → Apr 2028 expected	pituitary deficiency	Columbia University	Recruiting	No outcome recorded
Phase 4	NCT03759301 Comparator	Dec 2018 → May 2019	female infertility	ClinAmygate	Completed	No outcome recorded
Phase 4	NCT03027843 Comparator	Mar 2017 → Aug 2019	ovarian dysfunction	Sun Yat-sen University	Unknown	No outcome recorded
Phase 4	NCT03015909 Background	Aug 2016 → Dec 2017	Turner syndrome, chronic renal failure syndrome, fetal growth restriction, isolated short stature +1	LG Life Sciences	Completed	No outcome recorded
Phase 4	NCT02766764 Comparator	Jun 2016 → Dec 2018	infertility disorder	Cairo University	Unknown	No outcome recorded
Phase 4	NCT01877512 Comparator	May 2013 → Apr 2014	cardiovascular disorder, metabolic syndrome X, pituitary deficiency	Amsterdam UMC, location VUmc	Completed	No outcome recorded
Phase 4	NCT00119769 Comparator	Feb 2005 → May 2007	HIV infectious disease, lipodystrophy	Hvidovre University Hospital	Completed	No outcome recorded
Phase 4	NCT00212758 Comparator	Jan 2005 → May 2008	chronic kidney disease, pituitary deficiency	Oregon Health and Science University	Completed	No outcome recorded
—	NCT02931591 Comparator	Nov 2016 → Nov 2019	fetal growth restriction	Cambridge University Hospitals NHS Foundation Trust	Unknown	No outcome recorded
—	NCT02782221 Comparator	May → Sep 2016	metabolic disease	University of Aarhus	Completed	No outcome recorded
—	NCT01724489 Comparator	Aug 2013 → Nov 2018	obesity disorder	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT01723748 Comparator	Dec 2012 → May 2015	acromegaly, metabolic disease	University of Aarhus	Completed	No outcome recorded
—	NCT00969644 Comparator	Sep 2009 → Mar 2010	growth hormone insensitivity syndrome with immune dysregulation	Herlev Hospital	Unknown	No outcome recorded
—	NCT00420654 Comparator	Aug 2007 → Sep 2011	Turner syndrome	Britta E. Hjerrild	Completed	No outcome recorded
—	NCT00491582 Comparator	Jul 2007 → Jul 2009	pituitary deficiency	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
—	NCT00182091 Comparator	Aug 2004 → Dec 2009	acromegaly, pituitary deficiency	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00100698 Comparator	Jan 2004 → Oct 2007	AIDS	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00136032 Comparator	Jan 2002 → Nov 2006	pituitary deficiency	Massachusetts General Hospital	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 16

Date	Issuer	Release
2026-04-21	Visen Pharmaceuticals (Shanghai) Co., Ltd.	Results China's briGHt Trial Published in Hormone Research in Paediatrics Further Confirms Once-Weekly Lonapegsomatropin as the Only Long-Acting Growth Hormone with Demonstrated Superiority Over Daily Somatropin visenpharma.com ↗ The trial showed that weekly lonapegsomatropin demonstrated non-inferiority and superiority over daily somatropin in annualized height velocity (AHV) among treatment-naive Chinese children with GHD.
2026-04-08	Ascendis Pharma A/S	Results New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia ascendispharma.com ↗ Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth with substantial improvements in arm span, spinal canal dimensions, and lower limb alignment.
2026-03-17	Ascendis Pharma A/S	Results New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 ascendispharma.com ↗ New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
2024-08-21	Changchun GeneScience Pharmaceutical Co., Ltd.	Regulatory Jintrolong® New Dosage Form of Long-acting Somatropin Injection Approved genscigroup.com ↗ August 20th, 2024, Shanghai-GenSci has announced that the New Drug Application for Jintrolong® Polyethylene Glycol Recombinant Human Somatropin Injection (hereinafter referred to as PEG-rhGH) has received approval from the Center for Drug Evaluation, NMPA.
2022-11-17	Visen Pharmaceuticals (Shanghai) Co., Ltd.	Results VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently the Only Long-Acting Growth Hormone Demonstrates Superior Annualized Height Velocity Compared to Daily hGH in Children with Growth Hormone Deficiency visenpharma.com ↗ The AHV was significantly higher for lonapegsomatropin than for the daily hGH from week 13 onward.
2020-10-08	Pfizer	Results Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency pfizer.com ↗ Top-line results from the study demonstrated that treatment with somatrogon once-weekly improved the mean overall Life Interference total score after 12 weeks of treatment (8.63) compared to treatment with somatropin administered once-daily (24.13).
2020-06-09	OPKO Health, Inc.	Results OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency opko.com ↗ Using the Full Analysis Set, the least squared means for the annual height velocity was higher in the somatrogon group (9.65 cm/year) than in the GENOTROPIN group (7.87 cm/year).
2020-03-05	Visen Pharmaceuticals (Shanghai) Co., Ltd.	Results VISEN Pharmaceuticals announces top-line results from the global phase III heiGHt Trial, authorized by Ascendis Pharma in China visenpharma.com ↗ In the primary analysis of the intent-to-treat population using ANCOVA, TransCon TM hGH demonstrated an AHV of 11.2 cm/year compared to 10.3 cm/year for the daily hGH.
2019-10-21	Pfizer	Results OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency pfizer.com ↗ Top-line results from the study demonstrated that treatment with somatrogon dosed once-weekly in pre-pubertal children with GHD was non-inferior to somatropin dosed once-daily with respect to height velocity at 12 months of treatment (the primary endpoint);
2016-12-30	OPKO Health, Inc.	Results OPKO Health Provides Update on hGH-CTP Clinical Programs opko.com ↗ On the primary endpoint of change in trunk fat mass from baseline to 26 weeks, there was no statistical difference between hGH-CTP and placebo.
2015-10-08	OPKO Health, Inc.	Results OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology opko.com ↗ The twelve months data confirm comparable response of hGH-CTP to daily Genotropin® as reflected by the twelve months IGF-1SDS profile, annual HV, HV SDS and safety profile.
2015-10-07	OPKO Health, Inc.	Results OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE) opko.com ↗ The twelve month data confirmed comparable response of hGH-CTP to daily Genotropin® as reflected by the twelve month pharmacodynamic, efficacy and safety profile.
2014-09-22	Daewoong Pharmaceutical Co. LTD.	Regulatory Daewoong Pharmaceutical’s growth hormone drug ‘Caretropin’ received approval for sale in Philippines daewoong.co.kr ↗ Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) announced on September 17 that its growth hormone drug ‘Caretropin’ and dedicated syringes obtained approval for sale in Philippines.
2011-07-04	Daewoong Pharmaceutical Co. LTD.	Regulatory Caretropin, liquid type growth hormone, obtains license from KFDA daewoong.co.kr ↗ Daewoong Pharmaceutical Co., Ltd (President Lee Jong Wook) has obtained a license for Caretropin, a liquid growth hormone product, from KFDA.
2009-06-30	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone) tevapharm.com ↗
2003-06-16	Alkermes, Inc.	Results Alkermes and Lilly Present Clinical Data for Inhaled Form of Human Growth Hormone; Phase I Results Presented at International Society for Aerosols in Medicine Conference alkermes.com ↗ Delivery of up to 92 mg of the AIR formulation of human growth hormone was well tolerated with no clinically significant changes in vital signs and pulmonary function observed in study participants.

All press releases naming this drug 53 releases

Date	Issuer	Release
2026-04-21	Visen Pharmaceuticals (Shanghai) Co., Ltd.	China's briGHt Trial Published in Hormone Research in Paediatrics Further Confirms Once-Weekly Lonapegsomatropin as the Only Long-Acting Growth Hormone with Demonstrated Superiority Over Daily Somatropin visenpharma.com ↗
2026-04-08	Ascendis Pharma A/S	New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia ascendispharma.com ↗
2026-03-17	Ascendis Pharma A/S	New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 ascendispharma.com ↗
2026-02-12	Teijin America, Inc.	Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Weekly Pediatric Growth Hormone Deficiency Treatment[Teijin Pharma] teijin.com ↗
2026-01-26	Visen Pharmaceuticals (Shanghai) Co., Ltd.	VISEN Receives China NMPA Approval for Once-Weekly Lonapegsomatropin for Pediatric Growth Hormone Deficiency visenpharma.com ↗
2025-10-09	Changchun GeneScience Pharmaceutical Co., Ltd.	From Long-acting Growth Hormone to Medical Devices: GenPEG Advances its High-purity Expertise genscigroup.com ↗
2025-05-20	Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone Leader genscigroup.com ↗
2024-08-21	Changchun GeneScience Pharmaceutical Co., Ltd.	Jintrolong® New Dosage Form of Long-acting Somatropin Injection Approved genscigroup.com ↗
2023-08-30	Genexine, Inc.	Genexine’s long-acting growth hormone meets Phase 3 primary endpoint genexine.com ↗
2023-06-28	Pfizer	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency pfizer.com ↗
2023-06-28	OPKO Health, Inc.	FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency opko.com ↗
2022-11-17	Visen Pharmaceuticals (Shanghai) Co., Ltd.	VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently the Only Long-Acting Growth Hormone Demonstrates Superior Annualized Height Velocity Compared to Daily hGH in Children with Growth Hormone Deficiency visenpharma.com ↗
2022-03-22	LG Life Sciences	LG Chem Develops Smart Case that Automates Injection Records to Improve Growth Hormone Customer Experience lgchem.com ↗
2022-02-15	Pfizer	Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency pfizer.com ↗
2022-02-15	OPKO Health, Inc.	Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency opko.com ↗
2022-01-21	Pfizer	Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency pfizer.com ↗
2022-01-21	OPKO Health, Inc.	Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency opko.com ↗
2022-01-20	OPKO Health, Inc.	JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY opko.com ↗
2021-12-17	Pfizer	EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency pfizer.com ↗
2021-09-24	Pfizer	Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency pfizer.com ↗
2021-09-24	OPKO Health, Inc.	Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency opko.com ↗
2021-04-06	Entera Bio Ltd.	New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress enterabio.com ↗
2021-03-30	Visen Pharmaceuticals (Shanghai) Co., Ltd.	VISEN’s TransCon TM Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Schedule visenpharma.com ↗
2021-02-26	Pfizer	EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency pfizer.com ↗
2021-02-26	OPKO Health, Inc.	EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency opko.com ↗
2021-01-28	OPKO Health, Inc.	New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency opko.com ↗
2021-01-04	Pfizer	US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency pfizer.com ↗
2021-01-04	OPKO Health, Inc.	US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency opko.com ↗
2020-10-08	Pfizer	Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency pfizer.com ↗
2020-10-08	OPKO Health, Inc.	Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency opko.com ↗
2020-06-09	OPKO Health, Inc.	OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency opko.com ↗
2020-04-21	Visen Pharmaceuticals (Shanghai) Co., Ltd.	TransCon TM hGH Received Orphan Drug Designation in the US and EC as Treatment for Growth Hormone Deficiency visenpharma.com ↗
2020-03-05	Visen Pharmaceuticals (Shanghai) Co., Ltd.	VISEN Pharmaceuticals announces top-line results from the global phase III heiGHt Trial, authorized by Ascendis Pharma in China visenpharma.com ↗
2019-10-21	Pfizer	OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency pfizer.com ↗
2019-10-21	OPKO Health, Inc.	OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency opko.com ↗
2019-08-29	OPKO Health, Inc.	OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency opko.com ↗
2018-08-03	OPKO Health, Inc.	OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children opko.com ↗
2017-04-03	Genexine, Inc.	Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017 genexine.com ↗
2017-02-21	Genexine, Inc.	CMC Biologics and Genexine Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9 genexine.com ↗
2016-12-30	OPKO Health, Inc.	OPKO Health Provides Update on hGH-CTP Clinical Programs opko.com ↗
2016-11-16	Genexine, Inc.	Genexine Granted FDA Orphan Drug Designation for GX-H9 in Growth Hormone Deficiency genexine.com ↗
2016-03-24	OPKO Health, Inc.	OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016 opko.com ↗
2015-10-08	OPKO Health, Inc.	OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology opko.com ↗
2015-10-07	OPKO Health, Inc.	OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE) opko.com ↗
2014-09-22	Daewoong Pharmaceutical Co. LTD.	Daewoong Pharmaceutical’s growth hormone drug ‘Caretropin’ received approval for sale in Philippines daewoong.co.kr ↗
2014-06-13	Daewoong Pharmaceutical Co. LTD.	Daewoong Pharmaceutical inks contracts to export Caretropin, a liquid growth hormone product, and syringes to three countries daewoong.co.kr ↗
2011-07-04	Daewoong Pharmaceutical Co. LTD.	Caretropin, liquid type growth hormone, obtains license from KFDA daewoong.co.kr ↗
2009-06-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone) tevapharm.com ↗
2005-02-11	Teva Branded Pharmaceutical Products R&D, Inc.	Teva And Savient Launch Tev-Tropin™ For Pediatric Growth Hormone Deficiency tevapharm.com ↗
2004-08-05	Teva Branded Pharmaceutical Products R&D, Inc.	Teva and Savient Receive Favorable Court Ruling on Human Growth Hormone Patent Suits tevapharm.com ↗
2004-06-01	Alkermes, Inc.	Genentech and Alkermes Announce Decision to Discontinue Commercialization of Nutropin Depot alkermes.com ↗
2003-06-16	Alkermes, Inc.	Alkermes and Lilly Present Clinical Data for Inhaled Form of Human Growth Hormone; Phase I Results Presented at International Society for Aerosols in Medicine Conference alkermes.com ↗
2000-03-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Pharmaceutical Industries Ltd. to Market BTG's Human Growth Hormone in the United States tevapharm.com ↗

Evidence & citations 50 cited values

Every value below carries the sentence it was read from. 344 sources stand behind the page.

Field	Value	Cited text
Known as	Somatropin	“Growth hormone (somatropin) administered by daily injection at starting dose of 0.3 mg daily for women and 0.2 mg daily for men, with dose titration for goal IGF-1 in the upper...” NCT02217345 ↗ 136 “The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous.” NCT03874013 ↗ “An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X” NCT00250250 ↗ “Norditropin® (somatropin [rDNA origin] injection) via FlexPro® 30 mg / 3ml strength auto-injector pens (Novo Nordisk Inc).” NCT04121780 ↗ “Injection of 10 iu of Somatropin and Platelet-Rich Plasma conjunct via intra-articular injection of the arthritic ankle.” NCT06907121 ↗ “Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months.” NCT00933686 ↗ “Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin.” NCT00663611 ↗ “personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA” NCT04375657 ↗ “additional treatment with GH (Somatropin, 4 IU/day, subcutaneous injection)” NCT05281341 ↗ “Sustained Release Formulation of Somatropin (rDNA Origin)for Injection” NCT00600808 ↗ “HumatropeR (somatropin) is currently approved by the FDA for:” NCT02124070 ↗ Show 126 more sources
Known as	ALTU-238	“ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults...” NCT00297713 ↗ 1 “Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin)” NCT00837863 ↗
Known as	Genotonorm	“The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA.” NCT00174408 ↗ 5 “Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary” NCT00174278 ↗ “Recombinant Human Growth Hormone Genotonorm (Registered)” NCT00174187 ↗ “Growth hormone (Genotonorm® or Omnitrope®)” NCT01298180 ↗ “Genotonorm (Somatropin)” NCT00174252 ↗ NCT01073605 ↗
Known as	Genotropin	“Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day...” NCT00929799 ↗ 33 “The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime.” NCT00781547 ↗ “Growth hormone (GH, Somatropin, e.g. Genotropin®) is approved in the treatment of children in specific indications.” NCT00488124 ↗ “commercially available rhGH (genotropin) 34 micrograms (μg)/kg once daily SC bolus injection for 12 months” NCT02339090 ↗ “Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg” NCT02782221 ↗ “Genotropin (PN-180,307) Somatropin” NCT00627523 ↗ “Genotropin (PN-180,307) Somatropin” NCT00432263 ↗ “Somatropin infusion (Genotropin®)” NCT02655263 ↗ “growth hormone (genotropin)” NCT00646815 ↗ “Genotropin (somatropin)” NCT01859949 ↗ NCT02879747 ↗ Show 23 more sources
Known as	Genotropin (Pfizer)	“growth hormone, Genotropin (Pfizer)” NCT02217345 ↗
Known as	Genotropin (Somatropin)	“Genotropin (Somatropin)” NCT01248416 ↗
Known as	Genotropin miniquick 0.5 mg, injection	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03878992 ↗
Known as	growth hormone	“The addition of growth hormone, which is a biological hormone that can be synthetically produced, as a supplement to gonadotrophins in an In Vitro Fertilization cycle has been...” NCT01715324 ↗ 83 “this study sought to assess the feasibility of increasing IGF-1 levels through recombinant human growth hormone (rhGH) treatment, in addition to establishing safety and...” PMID 35093163 ↗ Jan 2022 “Growth hormone (somatropin) administered by daily injection at starting dose of 0.3 mg daily for women and 0.2 mg daily for men, with dose titration for goal IGF-1 in the upper...” NCT02217345 ↗ “Growth hormone (GH) replacement in GH deficient adults results in an improvement in metabolic status, an increase in lean body mass and a reduction in visceral adiposity.” NCT00453557 ↗ “patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline)” NCT06379659 ↗ “Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup” NCT03759301 ↗ “the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment.” NCT04507945 ↗ “Growth hormone (GH, Somatropin, e.g. Genotropin®) is approved in the treatment of children in specific indications.” NCT00488124 ↗ “Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary” NCT00174278 ↗ “daily doses of exogenous growth hormone (GH) in patients with traumatic spinal cord injury” NCT01329757 ↗ “Growth hormone 2 mg once a day administered by subcutaneous injection” NCT01265017 ↗ Show 73 more sources
Known as	Growth Hormone (Nutropin AQ)	“Growth Hormone (Nutropin AQ)” NCT00134420 ↗
Known as	Growth Hormone, Human	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06558422 ↗ 2 NCT05724134 ↗ NCT07359625 ↗
Known as	hGH	“The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).” NCT00455260 ↗ 4 “Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy” NCT01778023 ↗ “somatropin (human growth hormone, hGH)” NCT02229851 ↗ “Human Growth Hormone (hGH)” NCT07568574 ↗ “hGH (somatropin)” NCT02382939 ↗
Known as	human growth hormone	“This study aims to examine the safety, tolerability and pharmacokinetics of transdermal delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult...” NCT00455260 ↗ 15 “The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival” NCT00503698 ↗ “Human growth hormone,ZOMACTON® (somatropin)” NCT02326610 ↗ “somatropin (human growth hormone, hGH)” NCT02229851 ↗ “human growth hormone (Genotropin)” NCT02781727 ↗ “Saizen (Human Growth Hormone)” NCT01616225 ↗ NCT00300664 ↗ NCT07568574 ↗ NCT03775993 ↗ NCT02179255 ↗ NCT06382155 ↗ Show 5 more sources
Known as	Human Growth Hormone (HGH)	“Human Growth Hormone (HGH)” NCT02179255 ↗
Known as	Humatrope	“Humatrope = Somatropin (rDNA origin) for injection” NCT00742157 ↗ 6 “Growth Hormone (Humatrope)” NCT00001221 ↗ NCT00757393 ↗ NCT00001343 ↗ NCT00001305 ↗ NCT00266656 ↗ NCT00675714 ↗
Known as	HumatropeR	“HumatropeR (somatropin) is currently approved by the FDA for:” NCT02124070 ↗
Known as	JINTOPIN AQ	“Recombinant Human Growth Hormone Injection (JINTOPIN AQ)” NCT03245333 ↗ 1 “Recombinant Human Growth Hormone Injection（JINTOPIN AQ）” NCT03221933 ↗
Known as	Jintropin AQ	“This was a multicenter, randomized, open-label, parallel controlled phase III study, compared pegylated somatropin with Jintropin AQ (somatropin liquid injection, daily...” NCT01495468 ↗
Known as	LY137998	“Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency” NCT00191360 ↗
Known as	MAXOMAT	“Biosynthetic Growth Hormone MAXOMAT ®” NCT00452491 ↗
Known as	NN-220	“subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime” NCT00184717 ↗ 1 “Norditropin® (NN-220; somatropin)” PMID 32269181 ↗ May 2020
Known as	Norditropin	“The aim of this trial is to evaluate the effect of somatropin (Norditropin®) on final height in children with Noonan syndrome having being treated for up to 10 years with...” NCT01529840 ↗ 23 “This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and...” NCT01502124 ↗ “The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data...” NCT01529944 ↗ “The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.” NCT01562834 ↗ “The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final height.” NCT01518062 ↗ “Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.” NCT01897324 ↗ “The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.” NCT00262249 ↗ “Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin.” NCT00663611 ↗ “Norditropin® will be administered s.c. once daily by FlexPro® pen-injector.” NCT03811535 ↗ “growth hormone (GH) therapy (Norditropin®; Novo Nordisk, Bagsværd, Denmark)” PMID 32595770 ↗ Oct 2019 “Recombinant Human Growth Hormone Injection (Norditropin®)” NCT07016802 ↗ Show 13 more sources
Known as	Norditropin (somatropin [rDNA origin] injection)	“Norditropin® (somatropin [rDNA origin] injection)” NCT04121780 ↗
Known as	Norditropin cartridges	“This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and...” NCT01502124 ↗
Known as	Norditropin FlexPro	“A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated...” NCT03075644 ↗ 3 “daily Norditropin® FlexPro® (somatropin delivered within a prefilled pen)” NCT02382939 ↗ “Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)” NCT07450053 ↗ “Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)” NCT07450001 ↗
Known as	Norditropin NordiFlex	“A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant” NCT00936403 ↗
Known as	Norditropin Nordilet	“Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy” NCT01778023 ↗
Known as	Norditropin SimpleXx	“An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected...” NCT01502137 ↗ 2 “daily dosing of Norditropin® SimpleXx® (somatropin) in children with growth hormone deficiency.” NCT01973244 ↗ “Norditropin SimpleXx (growth hormone)” NCT01090778 ↗
Known as	Nutropin	“Patients will be treated with growth hormone in the form of Nutropin (a powder formulation that is reconstituted by the patient) or Nutropin AQ (a ready-to-use liquid) for 1 year.” NCT00287430 ↗ 6 “The second group drinks 8 ounces of a high-calorie beverage called Pediasure every day for 6 months and then receives Nutropin plus Pediasure every day for 12 months.” NCT00102258 ↗ “GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial” NCT00133354 ↗ “Nutropin [Somatropin (rDNA origin) for injection]” NCT01438801 ↗ “growth hormone (Nutropin)” NCT00362063 ↗ NCT00518635 ↗ NCT00286676 ↗
Known as	Nutropin (Somatropin)	“Nutropin (Somatropin)” NCT01248416 ↗
Known as	Nutropin AQ	“Patients will be treated with growth hormone in the form of Nutropin (a powder formulation that is reconstituted by the patient) or Nutropin AQ (a ready-to-use liquid) for 1 year.” NCT00287430 ↗ 11 “Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months.” NCT00131378 ↗ “Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin)” NCT00837863 ↗ “Nutropin AQ [somatropin (DNA origin) injection]” NCT00079742 ↗ “NutropinAq® (Somatropin [rDNA origin])” NCT00572156 ↗ NCT00134420 ↗ NCT00444964 ↗ NCT01020955 ↗ NCT00140413 ↗ NCT00212758 ↗ NCT00803179 ↗ Show 1 more source
Known as	Nutropin depot	“depot GH (Nutropin depot) 13.4 mg every 14 days” NCT00149708 ↗
Known as	Omnitrope	“pharmacodynamics (PD) of a single dose of TransCon GH as compared to equivalent doses of daily GH (Omnitrope) or placebo in healthy adults.” PMID 29273485 ↗ Dec 2017 3 “Growth hormone (Genotonorm® or Omnitrope®)” NCT01298180 ↗ NCT01247675 ↗ NCT00537914 ↗
Known as	PN-180,307	“Genotropin (PN-180,307) Somatropin” NCT00432263 ↗ 1 “Genotropin (PN-180,307) Somatropin” NCT00627523 ↗
Known as	rcGH	“recombinant human growth hormone (rcGH)” NCT00244075 ↗
Known as	recombinant growth hormone	“Somatropin, also known as recombinant growth hormone (rhGH), is one of the World Anti-Doping Agency (WADA) prohibited substances.” NCT04042428 ↗
Known as	recombinant human GH	“Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day...” NCT00929799 ↗ 1 “supplementation with recombinant human GH (rh-GH) during ovarian stimulation (OS) may improve the ovarian response and clinical outcomes of IVF” PMID 37858247 ↗ Oct 2023
Known as	recombinant human growth hormone	“An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected...” NCT01502137 ↗ 48 “Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with...” NCT05724134 ↗ “The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the...” NCT01647412 ↗ “ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults...” NCT00297713 ↗ “Recombinant human growth hormone (GH; somatropin) treatment has beneficial effects on body composition in patients with Prader-Willi syndrome (PWS).” PMID 40436776 ↗ May 2025 “Phase IV Clinical Study Evaluating Efficacy and Safety of Recombinant Human Growth Hormone Injection for Adult Short Bowel Syndrome” NCT07691125 ↗ “Patients are randomized to receive either placebo or recombinant human growth hormone subcutaneously every other day for 6 months.” NCT00004429 ↗ “Patients are randomly assigned to recombinant human growth hormone (GH) and oxandrolone versus GH and placebo.” NCT00004275 ↗ “STUDY PRODUCT: Somatropin, recombinant human growth hormone (rhGH), Saizen® 8 mg (24 IE).” NCT04420481 ↗ “personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA” NCT04375657 ↗ “Somatropin; Recombinant human growth hormone (r hGH)” NCT00489528 ↗ Show 38 more sources
Known as	rGH	“It is hypothesized that the weekly injections of recombinant human growth hormone (rGH) into the knee joint of patients suffering from OA will act upon chondrocyte progenitor...” NCT06354023 ↗
Known as	rhGH	“Our objective was to characterize the prevalence of GH deficiency (GHD) testing and response to recombinant human GH (rhGH) treatment in adults with persistent symptoms...” PMID 33879807 ↗ Apr 2021 31 “This study is a multicenter, randomized controlled trial aimed at evaluating the effectiveness and safety of recombinant human growth hormone (rhGH) in elderly patients who...” NCT07481656 ↗ “The study's purpose was to use recombinant human growth hormone (rhGH) as a physiologic probe to assess the effects of reversing obesity-related GH deficiency on body...” PMID 25435886 ↗ Nov 2014 “this study sought to assess the feasibility of increasing IGF-1 levels through recombinant human growth hormone (rhGH) treatment, in addition to establishing safety and...” PMID 35093163 ↗ Jan 2022 “This study has one primary hypothesis, that treatment with recombinant human Growth Hormone (rhGH) in the subacute period after TBI results in improved functional outcome 6...” NCT00766038 ↗ “Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with...” NCT05724134 ↗ “The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the...” NCT01647412 ↗ “ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults...” NCT00297713 ↗ “administration of recombinant human growth hormone (rhGH) will result in growth rate stimulation in pre-pubertal children with growth impairment due to chronic kidney disease” NCT00194961 ↗ “Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected patients but can worsen glucose homeostasis and lipoatrophy.” PMID 23593417 ↗ Apr 2013 “In summary, this piot study with 6 participants shown that recombinant human growth hormone (rhGH) has a positive effect on the treatment with PMS.” NCT05105685 ↗ Show 21 more sources
Known as	rhGH from Teva Pharmaceuticals	“rhGH from Teva Pharmaceuticals” NCT00795210 ↗
Known as	Saizen	“Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day” NCT00256126 ↗ 11 “Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months.” NCT00933686 ↗ “The investigational product is rHGH (Saizen (somatropin of rDNA origin, EMD Serono)) and a saline placebo.” PMID 41638751 ↗ Feb 2026 “patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC” NCT01130376 ↗ “STUDY PRODUCT: Somatropin, recombinant human growth hormone (rhGH), Saizen® 8 mg (24 IE).” NCT04420481 ↗ NCT01616225 ↗ NCT01237340 ↗ NCT00249821 ↗ NCT01400698 ↗ NCT00256126 ↗ NCT01746862 ↗ Show 1 more source
Known as	Saizen (Somatoptropin; Human growth hormone)	“Saizen (Somatoptropin; Human growth hormone)” NCT01204840 ↗
Known as	Serostim	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00082628 ↗ 3 NCT00294164 ↗ NCT01077960 ↗ NCT00294918 ↗
Known as	Somatotropin	“in addition to Growth hormone (GH; Somatotropin, Sedico, Egypt) 4 IU on day 6 of human menopausal gonadotropin (hMG) stimulation in a daily dose of 2.5 mg subcutaneous (sc)...” NCT02766764 ↗
Known as	Somatropin (rDNA origin)	“Nutropin [Somatropin (rDNA origin) for injection]” NCT01438801 ↗
Known as	ZOMACTON	“An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X” NCT00250250 ↗ 2 “Human growth hormone,ZOMACTON® (somatropin)” NCT02326610 ↗ NCT00884000 ↗
Action	Restore	“growth hormone replacement” NCT00136032 ↗
Modality	Protein / enzyme biologic	“recombinant human growth hormone” PMID 21449786 ↗ Mar 2011
Route	Other	“growth hormone injections” NCT00001343 ↗
Target	GHR	“GH exerts its biological effects through binding to site 1 and 2 on the extracellular domain of a preformed GHR dimer” NCT03878992 ↗